Therefore, the FDA approval of omalizumab (anti-IgE monoclonal antibody) for the reduction in allergic reactions that may occur with an accidental exposure to one or more foods in adults and children aged 1 year and older with IgE-mediated food allergy in February 2024 marks a milestone in the treatment of food allergies [10,11]. This evidence concerns the gene IGHE and allergic disease.